Families of opioid victims express frustration with the process

  • Supreme Court weighs legality of Purdue Pharma’s bankruptcy settlement
  • Relatives of opioid victims express frustration with the process
  • Settlement gives Sackler family broad protections against civil claims
  • Fewer than 20% of eligible claimants voted on the plan
  • Protesters gather outside Supreme Court to voice opposition to the settlement
  • Justices raise questions about the impact of the settlement on opioid victims

The U.S. Supreme Court is currently considering the legality of Purdue Pharma’s bankruptcy settlement, which has sparked frustration among relatives of opioid victims. The settlement, which involves the maker of OxyContin, grants the Sackler family broad protections against civil claims. However, fewer than 20% of eligible claimants voted on the plan, and some traveled to Washington to protest the settlement. Justices raised questions about the impact of the settlement on opioid victims, highlighting the need to consider the rights of those who were unknowingly pulled into the bankruptcy process.

Public Companies: Purdue Pharma (N/A)
Private Companies:
Key People: Curtis Gannon (Deputy Solicitor General), Cynthia Munger (N/A), Ed Bisch (Founder of Relatives Against Purdue Pharma), Sue Crathern (N/A), Edward Neiger (Lawyer at ASK LLP), Justice Brett Kavanaugh (Supreme Court Justice)

Factuality Level: 7
Justification: The article provides information about the Supreme Court weighing the legality of Purdue Pharma’s bankruptcy settlement and the concerns raised by relatives of opioid victims. It includes quotes from justices and individuals affected by the settlement. The article does not contain irrelevant or misleading information, but it does include some personal perspectives and opinions from those involved. Overall, the article provides a factual account of the situation while also presenting different viewpoints.

Noise Level: 7
Justification: The article provides a detailed account of the Supreme Court hearing on Purdue Pharma’s bankruptcy settlement and includes perspectives from relatives of opioid victims. It discusses the arguments made by both sides and highlights the concerns raised by the justices. However, the article lacks scientific rigor and intellectual honesty as it does not provide a balanced analysis of the long-term trends or possibilities related to the opioid epidemic and the accountability of powerful people involved. It also does not offer actionable insights or solutions for addressing the issue.

Financial Relevance: No
Financial Markets Impacted: No

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: This news article does not pertain to financial topics and does not describe any extreme event.

Reported publicly: www.marketwatch.com